English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/143477
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease

Autord’Anglemont de Tassigny, Xavier; Pascual Bravo, Alberto ; López-Barneo, José
Palabras claveStriatum
Nigrostriatal pathway
Dopaminergic system
Mouse models
Neurotrophic factors
GDNF
Parkinson disease
Parvalbumin interneurons
Fecha de publicación15-feb-2015
EditorFrontiers Media
CitaciónFrontiers in neuroanatomy 9: 10 (2015)
ResumenThe glial cell line-derived neurotrophic factor (GDNF) is a well-established trophic agent for dopaminergic (DA) neurons in vitro and in vivo. GDNF is necessary for maintenance of neuronal morphological and neurochemical phenotype and protects DA neurons from toxic damage. Numerous studies on animal models of Parkinson’s disease (PD) have reported beneficial effects of GDNF on nigrostriatal DA neuron survival. However, translation of these observations to the clinical setting has been hampered so far by side effects associated with the chronic continuous intra-striatal infusion of recombinant GDNF. In addition, double blind and placebo-controlled clinical trials have not reported any clinically relevant effect of GDNF on PD patients. In the past few years, experiments with conditional Gdnf knockout mice have suggested that GDNF is necessary for maintenance of DA neurons in adulthood. In parallel, new methodologies for exogenous GDNF delivery have been developed. Recently, it has been shown that a small population of scattered, electrically interconnected, parvalbumin positive (PV+) GABAergic interneurons is responsible for most of the GDNF produced in the rodent striatum. In addition, cholinergic striatal interneurons appear to be also involved in the modulation of striatal GDNF. In this review, we summarize current knowledge on brain GDNF delivery, homeostasis, and its effects on nigrostriatal DA neurons. Special attention is paid to the therapeutic potential of endogenous GDNF stimulation in PD.
Versión del editorhttp://doi.org/10.3389/fnana.2015.00010
URIhttp://hdl.handle.net/10261/143477
DOI10.3389/fnana.2015.00010
Identificadoresissn: 1662-5129
Aparece en las colecciones: (IBIS) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
GDNF-based_therapies_Anglemont.pdf1,5 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.